Navigation Links
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
Date:11/5/2007

SAN MARINO, Calif., Nov. 5 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials in the United States for pancreatic cancer, breast cancer and all types of sarcoma in the summer of 2007.

*(LOGO: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

Based on the exceptional safety profile of Rexin-G in the first 18 patients who participated in these U.S.-based clinical trials, and the profound demonstration of single agent efficacy in metastatic osteosarcoma, the FDA approved a Phase II Registration Protocol using intravenous Rexin-G for recurrent or metastatic osteosarcoma that is refractory to known therapies. The study will recruit 20-30 patients in 12-18 months. Children who are at least 10 years of age or older are eligible to participate in the study. The adaptive trial design of this advanced Phase II registration protocol incorporates (i) a dosing schedule based on the patient's estimated tumor burden and not on standard dosing per kilogram body weight or body surface area, and (2) a tumor response evaluation process that is unique to the manner in which osteosarcoma responds favorably to therapy, i.e., with necrosis and increasing calcification in metastatic tumors and decreased glucose utilization using PET-CT imaging studies.

Rexin-G is a tumor-targeted gene medicine that seeks out and destroys both primary tumor and metastatic cancers that have spread throughout the body. Delivered by simple intravenous infusion, Rexin-G has demonstrated unprecedented single-agent efficacy against a broad spectrum of solid tumors where chemotherapy, radiotherapy a
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... brain health. , The study, performed by the University ... 60 and 78 over a week-long period and observed ... daily physical activity. By examining the structural soundness of ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... Commission Accredited teleradiology and specialty telemedicine solutions provider, ... addition to its existing teleradiology services at Mission ... opinion and expert telemedicine services, to the state-of-the-art, ... As a result of this innovative partnership, there ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... , , , ... CareFusion Corporation, the company that will become publicly traded following ... of Cardinal Health, today announced it has expanded its Pyxis((R)) ... (ORIS), incorporate radio-frequency identification (RFID) technology(1) and include new services. ...
... , , MENTOR, Ohio, July 20 ... issue its fiscal 2010 first quarter earnings before the market opens on ... time. The conference call can be heard live over the Internet at ... the United States and Canada, and 1-773-799-3378 internationally, then referencing the password ...
... , CHAPEL HILL, N.C., July 20 RealMed ... partnership to provide RealMed EDI Revenue Management Services to clients ... RealMed will provide services including online ECS claims filing, editing ... Eligibility Verification). In return, TSI Healthcare has committed ...
... The PBCC Announces availability of conference scholarships ... for the 2009 PA Breast Cancer Coalition Annual Conference , ... Coalition (PBCC) is proud to announce the availability of scholarships and travel grants for ... at the Harrisburg Hilton & Towers on Wednesday, October 14, 2009. , ...
... , , SKILLMAN, ... octuplets Nadya Suleman and "Jon & Kate Plus 8" has American ... fertilization (IVF). The recent e.p.t((R)) /BabyCenter ((R)) Fertility Report* ... believe that public visibility of large families and multiple births are ...
... , HOUSTON, July 20 What will healthcare look ... If you would like to learn more and have an opportunity to make ... morning-long forum on "Building a Federal Health Board: The Impact on Texas." ... St. Joseph Medical Center, 1401 St. Joseph Parkway in Houston, Texas on Wednesday, ...
Cached Medicine News:Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 2Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 3Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 4Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 5Health News:STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call 3Health News:RealMed Corporation and TSI Healthcare Announce Strategic Partnership 2Health News:Scholarships Available for PA Breast Cancer Coalition Annual Conference 2Health News:New e.p.t.(R)/BabyCenter(R) Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization 2Health News:New e.p.t.(R)/BabyCenter(R) Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization 3Health News:New e.p.t.(R)/BabyCenter(R) Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization 4Health News:Building a Federal Health Board - Impact on Texas 2
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
(Date:10/30/2014)... , Oct. 30, 2014  The number of ... is growing steadily, thanks to drug store ... a result of the economic downturn, retail clinic growth ... year of opportunities, as the number of retail clinics ... report, Retail Clinics Market Overview and 2014 Consumer ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
Picofluor™ Fluorometer is a lightweight, inexpensive, handheld fluorometer, configured for the fluorescent probes commonly used for nucleic acid and protein quantitation....
Inquire...
The FluoroMax-3 is the entry level spectrofluorometer from Spex®, yet offers features not found in most of the top models of the competition....
... The BTF-111 miniature ... a user-con?gured spectrometer for ... nm. Con?gurable excitation light ... ?exibility of 2D ?uorescence ...
Medicine Products: